For example, patritumab deruxtecan, a HER3-directed ADC, has shown promising efficacy in EGFR-mutated NSCLC [167], while tusamitamab ravtansine, targeting CEACAM5, has demonstrated anti-tumor activity in preclinical models and early-phase studies [168, 169]. Here, CEACAM5 is linked to neoplasm.